Step 1 topics → Respiratory → Antitussives, Expectorants, and Antihistamines (H1 Blockers)

Antitussives, Expectorants, and Antihistamines (H1 Blockers)

USMLE Step 1 trap: Incorrectly attributes dextromethorphan's antitussive effect to opioid receptor agonism. Dextromethorphan suppresses cough via NMDA receptor antagonism and sigma receptor agonism, with no significant opioid receptor activity at therapeutic doses.

Antitussives, expectorants, and antihistamines are a cluster of respiratory pharmacology concepts that show up occasionally on USMLE Step 1, mostly in the context of mechanism identification or drug interaction questions. The core drugs here — dextromethorphan, codeine, guaifenesin, and the H1 blockers — are familiar from everyday life, which is exactly why students get them wrong. Familiarity breeds carelessness. The exam exploits what you think you already know.

Step 1 tests this material in a few predictable ways: direct mechanism recall (what receptor does dextromethorphan act on?), clinical application (why is diphenhydramine sedating but loratadine isn't?), and drug interaction reasoning (what happens when you combine dextromethorphan with an MAOI?). The passage-based questions often bury the relevant drug in a case about overdose, polysubstance use, or drug-drug interactions — so you need to know not just what these drugs do, but what goes wrong with them.

The biggest traps are the ones that come from superficial pattern-matching. Students lump dextromethorphan with codeine because both suppress cough, assume guaifenesin works like NAC because both affect mucus, and think first-generation antihistamines sedate because they're 'stronger.' None of those models are correct. This topic rewards precision over familiarity.

From real student decks
68%have cards covering this topic
46%have mature cards

Common misconceptions

Common mistake
Wrong: Dextromethorphan suppresses cough by acting on mu-opioid receptors like codeine.
Right: Dextromethorphan suppresses cough via NMDA receptor antagonism and sigma receptor agonism, with no significant opioid receptor activity at therapeutic doses.
Dextromethorphan looks like an opioid structurally and shares the antitussive effect of codeine, so it's tempting to assume they work the same way. But at therapeutic doses, dextromethorphan has negligible activity at mu-opioid receptors — its antitussive effect comes from NMDA receptor antagonism and sigma receptor agonism. This distinction matters clinically: dextromethorphan doesn't cause opioid-type respiratory depression or dependence at normal doses, and naloxone won't reverse its effects.
Common mistake
Gap: Missing that dextromethorphan's serotonergic activity creates a dangerous interaction with MAOIs
Dextromethorphan inhibits serotonin reuptake and can precipitate serotonin syndrome when combined with MAOIs or other serotonergic drugs.
Most students know dextromethorphan as a cough suppressant and never think about its serotonergic activity. But dextromethorphan inhibits serotonin reuptake, which means combining it with MAOIs, SSRIs, or other serotonergic agents can push synaptic serotonin dangerously high. USMLE Step 1 loves MAOI interaction questions, and DXM is one of the less obvious culprits — if a vignette mentions an MAOI and any OTC cold medicine, serotonin syndrome should be on your radar.
Common mistake
Wrong: Guaifenesin breaks down mucus by cleaving disulfide bonds.
Right: Guaifenesin is an expectorant that increases respiratory tract secretions and reduces mucus viscosity by increasing hydration of mucus, facilitating ciliary clearance; it does not cleave disulfide bonds.
The disulfide-bond-cleaving mechanism belongs to N-acetylcysteine (NAC), not guaifenesin. Guaifenesin is an expectorant, not a mucolytic — it works by increasing the volume of respiratory tract secretions, which dilutes and hydrates mucus, making it easier for cilia to clear. It doesn't chemically alter mucus structure at all. When the exam asks about a drug that 'thins mucus by breaking disulfide bonds,' the answer is NAC; guaifenesin works upstream by just adding water.
Common mistake
Wrong: First-generation antihistamines cause sedation solely because they are more potent H1 blockers than second-generation agents.
Right: First-generation antihistamines cause sedation because they cross the blood-brain barrier and block central H1 receptors; second-generation agents are equally potent peripherally but are non-sedating due to poor CNS penetration.
First and second generation H1 blockers are roughly equivalent in peripheral H1 receptor potency — the sedation difference isn't about how strongly they bind. The real difference is lipophilicity and CNS penetration. First-generation agents like diphenhydramine are lipophilic and cross the blood-brain barrier readily, blocking central H1 receptors that normally promote wakefulness. Second-generation agents like loratadine and fexofenadine are less lipophilic and/or are actively pumped out of the CNS, so they stay peripheral and don't cause sedation.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the distinct mechanisms of dextromethorphan (NMDA receptor antagonism, sigma receptor agonism) versus codeine (mu-opioid receptor agonism) — the exam will try to swap these or ask you to distinguish them.
  2. Recognize that dextromethorphan inhibits serotonin reuptake and can precipitate serotonin syndrome when combined with MAOIs or other serotonergic drugs — this is a clinically dangerous interaction worth knowing cold.
  3. Understand that guaifenesin works by hydrating mucus to reduce viscosity and facilitate clearance — not by cleaving disulfide bonds, which is N-acetylcysteine's mechanism.
  4. Explain why first-generation antihistamines (diphenhydramine) cause sedation and second-generation agents (loratadine, fexofenadine, cetirizine) do not — the answer is CNS penetration, not receptor potency.

Can you avoid these mistakes?

A patient taking phenelzine for depression takes an OTC cold medication containing dextromethorphan. Two hours later he develops agitation, diaphoresis, and myoclonus. What is the mechanism behind dextromethorphan's contribution to this reaction?
A pharmacology question asks which drug reduces mucus viscosity by cleaving disulfide bonds in mucus glycoproteins. A student answers guaifenesin. What drug should have been selected instead, and why is guaifenesin wrong?
Why does diphenhydramine cause drowsiness while loratadine does not, even though both block H1 receptors with similar peripheral potency?
A patient with a non-productive cough asks for something to suppress it. You recommend dextromethorphan. A classmate says it's basically a weak opioid. How would you explain why that's incorrect, and what receptor mechanism actually accounts for its antitussive effect?

Related topics

Lung Development Stages Surfactant Production and Neonatal RDS Bronchopulmonary Dysplasia Congenital Diaphragmatic Hernia

See how your Anki deck covers this topic.

Upload your deck for a free audit →